Reports Q2 revenue $5.94B, consensus $5.83B. Rainer Blair, president and CEO, stated, “Our team’s strong execution using the Danaher (DHR) Business System, paired with another quarter of robust growth in our Bioprocessing business and disciplined cost management, enabled us to exceed our expectations for the quarter.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DHR:
- Notable companies reporting before tomorrow’s open
- Danaher price target raised to $226 from $225 at Baird
- ‘Too Cheap to Ignore’: Scotiabank Says There’s an Opportunity Brewing in These 2 Large Cap Healthcare Stocks
- Scotiabank upgrades Danaher with ‘worst-case’ priced in
- Danaher upgraded to Outperform from Sector Perform at Scotiabank